Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.75
-0.3000-14.63%
Pre-market: 1.750.00000.00%06:19 EDT
Volume:1.15M
Turnover:2.06M
Market Cap:14.79M
PE:-0.57
High:1.91
Open:1.90
Low:1.57
Close:2.05
52wk High:3.79
52wk Low:0.8200
Shares:8.45M
Float Shares:8.41M
Volume Ratio:3.33
T/O Rate:13.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0500
EPS(LYR):-3.0500
ROE:-150.76%
ROA:-79.06%
PB:1.44
PE(LYR):-0.57

Loading ...

U.S. Stocks on the MOVE-Forgent Power, Vera Bradley, Wells Fargo

Reuters
·
17 hours ago

BioVie Falls After Long COVID Drug Fails to Show Benefit in Overall Trial

Reuters
·
Yesterday

BioVie announces topline results from ADDRESS-LC trial

TIPRANKS
·
Yesterday

BioVie Announces Topline Results from Phase 2 Address‑Lc Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid

THOMSON REUTERS
·
Yesterday

BioVie - 41.6% of Bezisterim Patients Experienced Adverse Events vs 55.9% for Placebo

THOMSON REUTERS
·
Yesterday

BioVie - Bezisterim Safety and Tolerability Profile Similar to Placebo

THOMSON REUTERS
·
Yesterday

BioVie - Bezisterim Shows Advantage over Placebo on 21 of 22 Endpoints in Phase 2 Trial

THOMSON REUTERS
·
Yesterday

NASDAQ Trade Halt Halt News Pending at 07:25 Am

Reuters
·
Yesterday

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

GlobeNewswire
·
Yesterday

BioVie Signs At-the-Market Equity Sales Agreement for up to $6.46 Million Class a Shares

Reuters
·
Sep 14

BioVie Inc Files for Atm Offering of up to About $6.5 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
Sep 14

Biovica Q1 FY27 Operating Loss Widens to SEK 20.33 Million; Net Sales Rise 56% to SEK 4.04 Million

Reuters
·
Sep 10

BioVie Seeks FDA End-of-Phase 2 Meeting to Advance Bezisterim Phase 3 Parkinson’s Trial Design

Reuters
·
Sep 08

BioVie Announces Update to Parkinson’s Phase 3 Development Program

THOMSON REUTERS
·
Sep 08

BioVie - Requests End-of-Phase 2 Meeting with FDA, Expects Feedback Before Year-End

THOMSON REUTERS
·
Sep 08

BioVie Completes Treatment Phase of Phase 2 Long COVID Trial for Bezisterim

Reuters
·
Aug 31

BioVie - Topline Results for Address-Lc Expected Before End of September 2026

THOMSON REUTERS
·
Aug 31

BioVie Announces Completion of Treatment Phase of Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid

THOMSON REUTERS
·
Aug 31

BioVie President and CEO Cuong V Do Acquires 15,210 Shares Worth $31,637.68

Reuters
·
Aug 29

Top Premarket Gainers

MT Newswires Live
·
Aug 19